Video

James List from Janssen: Proven Hypothesis Provides Hope for Future Obesity Care

Author(s):

Even as gastric bypass continues to be a proven surgical option in the fight against the obesity epidemic work still remains to find a therapeutic option for this patient population as well.

Even as gastric bypass continues to be a proven surgical option in the fight against the obesity epidemic work still remains to find a therapeutic option for this patient population as well.

James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism at Janssen discussed a study the company has done looking at combining two popular medications in an effort to provide even greater benefit for obese patients. List discussed the study during the annual meeting of the American Diabetes Association in New Orleans.

Related Videos
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Jörn Schattenberg, MD | Credit: Novo Nordisk
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
© 2024 MJH Life Sciences

All rights reserved.